Format

Send to

Choose Destination
Amyotroph Lateral Scler. 2011 Jan;12(1):1-10. doi: 10.3109/17482968.2010.502940. Epub 2010 Aug 11.

The epidemiology and treatment of ALS: focus on the heterogeneity of the disease and critical appraisal of therapeutic trials.

Author information

1
Istituto di Ricerche Farmacologiche "Mario Negri", Via G. la Masa 19, 20156 Milano, Italy. ettore.beghi@marionegri.it

Abstract

Effective treatments for amyotrophic lateral sclerosis (ALS) have remained elusive. Only riluzole, a drug thought to affect glutamate metabolism, improves survival albeit to modest extent. Explanations for the negative results of therapeutic trials include a likely heterogeneity, both in disease susceptibility and pathogenic mechanisms, and faulty methodology of clinical trials. Further understanding of these factors will lead to improvements in patient stratification, and in the design of future clinical trials.

PMID:
20698807
PMCID:
PMC3513399
DOI:
10.3109/17482968.2010.502940
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center